Category: Side Effect: Cardiovascular (heart attack, stroke, heart failure, PE, DVT)
-
As Bayer Settlements For YAZ, Yasmin, Ocella, And Gianvi Continue In 2013, Total Payments Will Go Over The $1 Billion Level
According To Bayer 2012 Annual Report, More Than 3200 Blood Clot Claims Remain Unsettled And Additional Lawsuits Are Anticipated By Drug Company (Posted by Tom Lamb at DrugInjuryWatch.com)To start, by my review, there is…
-
Some Newer Contraceptive Methods Such As NuvaRing And YAZ / Yasmin Are Under Increasing Scrutiny Over In Europe
Is The FDA Doing Enough About Birth Control Products That Contain Third Generation Or Fourth Generation Progestins And Are Associated With Higher Risks Of Blood Clots (Posted by Tom Lamb at DrugInjuryWatch.com) A January 3,…
-
December 2012 Pradaxa Label Change: Contraindication: Use By Mechanical Heart Valves Patients
A Look At The Events And The Evidence Leading Up To This Latest FDA Action Concerning The Safety Of Pradaxa (Posted by Tom Lamb at DrugInjuryWatch.com) We set the stage with this December 19,…
-
November 2012 Litigation And Settlements Update: YAZ, Yasmin, Ocella, And Gianvi Lawsuits
Bayer Has Settled Less Than Half The DVT And PE Blood Clot Claims Filed Or Cases Subject To Tolling Agreements (Posted by Tom Lamb at DrugInjuryWatch.com) In late October 2012 we received the Bayer Stockholders’ Newsletter…
-
Fresenius GranuFlo Product Has Been Associated With Heart Problems And Cardiopulmonary Arrest During Dialysis Treatment
Fresenius Failed To Warn About Risks Of Sudden Heart Attack, Stroke, And Death Caused By GranuFlo Increasing The Level Of Bicarbonate In Blood (Posted by Tom Lamb at DrugInjuryWatch.com) ______________________________________________________________________________ UPDATE: Federal court GranuFlo…
-
NuvaRing: Plaintiffs’ Expert Reports Made Available By New Jersey Judge Based On Public’s Right Of Access To Judicial Proceedings
Defendants Had Sought To Keep Sealed Some Documents That Show NuvaRing Estrogen Levels Were Apparently Concealed Or Misrepresented By Organon (Posted by Tom Lamb at DrugInjuryWatch.com) ______________________________________________________________________________ UPDATE: A similar Order was issued on…
-
New Obesity Drug Qsymia / Qsiva Gets Gets Negative Opinion By European Medicines Agency (EMA)
Combination Pill Of Topamax And Phentremine Was Approved By FDA, But EMA Points To Heart Side Effects, Birth Defects, And Other Safety Issues (Posted by Tom Lamb at DrugInjuryWatch.com) On October 18, 2012 European drug regulators…
-
Disturbing Information About NuvaRing Safety Found In Motions On Experts Recently Unsealed By Federal Court MDL Judge
Newly Available Expert Analysis Of Confidential Drug Company Data Reveals That NuvaRing Estrogen Levels In Studies Were A Cause For Concern, And The Method Of Reporting Was Misleading (Posted by Tom Lamb at DrugInjuryWatch.com)…
-
2012 FDA Report On Beyaz Points Out That Younger Women and Girls Are Most At-Risk For Blood Clots
Approved By FDA In 2010, There Has Been No Study Done Yet Regarding Beyaz Safety — Despite Significant Number Of Beyaz Adverse Event Reports (Posted by Tom Lamb at DrugInjuryWatch.com) _____________________________________________________________________ UPDATE: FDA Meeting…
-
Multiple Sclerosis (MS) Medication Gilenya: Timeline Of Actions Taken In US, Canada, And Europe
Increasing Safety Concerns About Novartis Drug Gilenya Are Primarily Cardiovascular Side Effects And Unexplained Death (Posted by Tom Lamb at DrugInjuryWatch.com) In August 2012 Health Canada issued the latest drug safety alert concerning Gilenya…